nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—SLC47A1—Imatinib—hematologic cancer	0.145	0.218	CbGbCtD
Famotidine—SLC47A1—Mitoxantrone—hematologic cancer	0.115	0.173	CbGbCtD
Famotidine—SLC22A2—Daunorubicin—hematologic cancer	0.0588	0.0882	CbGbCtD
Famotidine—SLC22A2—Cytarabine—hematologic cancer	0.0518	0.0778	CbGbCtD
Famotidine—SLC22A2—Cladribine—hematologic cancer	0.0489	0.0735	CbGbCtD
Famotidine—SLC22A2—Imatinib—hematologic cancer	0.045	0.0676	CbGbCtD
Famotidine—SLC22A8—Mercaptopurine—hematologic cancer	0.039	0.0586	CbGbCtD
Famotidine—SLC22A2—Vinblastine—hematologic cancer	0.025	0.0375	CbGbCtD
Famotidine—SLC22A2—Cisplatin—hematologic cancer	0.0229	0.0344	CbGbCtD
Famotidine—CYP2C19—Bortezomib—hematologic cancer	0.0203	0.0304	CbGbCtD
Famotidine—CYP2C19—Thalidomide—hematologic cancer	0.0177	0.0265	CbGbCtD
Famotidine—CYP2C19—Teniposide—hematologic cancer	0.0168	0.0253	CbGbCtD
Famotidine—CYP2C19—Ifosfamide—hematologic cancer	0.0155	0.0233	CbGbCtD
Famotidine—CYP2C19—Imatinib—hematologic cancer	0.0148	0.0223	CbGbCtD
Famotidine—SLC22A8—Methotrexate—hematologic cancer	0.0128	0.0192	CbGbCtD
Famotidine—CYP2C19—Prednisone—hematologic cancer	0.00978	0.0147	CbGbCtD
Famotidine—CYP2C19—Dexamethasone—hematologic cancer	0.00611	0.00917	CbGbCtD
Famotidine—HRH2—hematopoietic system—hematologic cancer	0.00185	0.133	CbGeAlD
Famotidine—SLC47A1—hematopoietic system—hematologic cancer	0.00143	0.103	CbGeAlD
Famotidine—HRH2—blood—hematologic cancer	0.00122	0.0884	CbGeAlD
Famotidine—SLC22A8—hematopoietic system—hematologic cancer	0.00109	0.079	CbGeAlD
Famotidine—SLC47A1—gonad—hematologic cancer	0.00108	0.0783	CbGeAlD
Famotidine—HRH2—lung—hematologic cancer	0.00107	0.0775	CbGeAlD
Famotidine—SLC47A1—blood—hematologic cancer	0.000945	0.0682	CbGeAlD
Famotidine—CYP2C19—hematopoietic system—hematologic cancer	0.000918	0.0662	CbGeAlD
Famotidine—SLC47A1—lung—hematologic cancer	0.000829	0.0598	CbGeAlD
Famotidine—SLC47A1—testis—hematologic cancer	0.000782	0.0564	CbGeAlD
Famotidine—HRH2—lymph node—hematologic cancer	0.000734	0.053	CbGeAlD
Famotidine—SLC22A8—blood—hematologic cancer	0.000725	0.0523	CbGeAlD
Famotidine—CYP2C19—blood—hematologic cancer	0.000608	0.0439	CbGeAlD
Famotidine—SLC47A1—lymph node—hematologic cancer	0.000567	0.0409	CbGeAlD
Famotidine—Insomnia—Betamethasone—hematologic cancer	3.86e-05	0.000137	CcSEcCtD
Famotidine—Bradycardia—Doxorubicin—hematologic cancer	3.85e-05	0.000137	CcSEcCtD
Famotidine—Paraesthesia—Betamethasone—hematologic cancer	3.83e-05	0.000136	CcSEcCtD
Famotidine—Paraesthesia—Dexamethasone—hematologic cancer	3.83e-05	0.000136	CcSEcCtD
Famotidine—Mental disorder—Methotrexate—hematologic cancer	3.83e-05	0.000136	CcSEcCtD
Famotidine—Rash—Gemcitabine—hematologic cancer	3.83e-05	0.000136	CcSEcCtD
Famotidine—Dermatitis—Gemcitabine—hematologic cancer	3.83e-05	0.000136	CcSEcCtD
Famotidine—Hypersensitivity—Etoposide—hematologic cancer	3.82e-05	0.000136	CcSEcCtD
Famotidine—Tinnitus—Epirubicin—hematologic cancer	3.82e-05	0.000136	CcSEcCtD
Famotidine—Headache—Gemcitabine—hematologic cancer	3.81e-05	0.000135	CcSEcCtD
Famotidine—Nausea—Vincristine—hematologic cancer	3.8e-05	0.000135	CcSEcCtD
Famotidine—Flushing—Epirubicin—hematologic cancer	3.8e-05	0.000135	CcSEcCtD
Famotidine—Hepatitis—Doxorubicin—hematologic cancer	3.79e-05	0.000135	CcSEcCtD
Famotidine—Hypersensitivity—Prednisolone—hematologic cancer	3.77e-05	0.000134	CcSEcCtD
Famotidine—Pharyngitis—Doxorubicin—hematologic cancer	3.76e-05	0.000134	CcSEcCtD
Famotidine—Dyspepsia—Dexamethasone—hematologic cancer	3.76e-05	0.000134	CcSEcCtD
Famotidine—Dyspepsia—Betamethasone—hematologic cancer	3.76e-05	0.000134	CcSEcCtD
Famotidine—Urticaria—Triamcinolone—hematologic cancer	3.74e-05	0.000133	CcSEcCtD
Famotidine—Dysgeusia—Methotrexate—hematologic cancer	3.73e-05	0.000133	CcSEcCtD
Famotidine—Asthenia—Etoposide—hematologic cancer	3.72e-05	0.000132	CcSEcCtD
Famotidine—Body temperature increased—Triamcinolone—hematologic cancer	3.72e-05	0.000132	CcSEcCtD
Famotidine—Oedema—Prednisone—hematologic cancer	3.72e-05	0.000132	CcSEcCtD
Famotidine—Anaphylactic shock—Prednisone—hematologic cancer	3.72e-05	0.000132	CcSEcCtD
Famotidine—Decreased appetite—Dexamethasone—hematologic cancer	3.71e-05	0.000132	CcSEcCtD
Famotidine—Decreased appetite—Betamethasone—hematologic cancer	3.71e-05	0.000132	CcSEcCtD
Famotidine—Nausea—Mitoxantrone—hematologic cancer	3.7e-05	0.000132	CcSEcCtD
Famotidine—Nausea—Irinotecan—hematologic cancer	3.7e-05	0.000132	CcSEcCtD
Famotidine—Infection—Prednisone—hematologic cancer	3.69e-05	0.000131	CcSEcCtD
Famotidine—Back pain—Methotrexate—hematologic cancer	3.68e-05	0.000131	CcSEcCtD
Famotidine—Fatigue—Dexamethasone—hematologic cancer	3.68e-05	0.000131	CcSEcCtD
Famotidine—Fatigue—Betamethasone—hematologic cancer	3.68e-05	0.000131	CcSEcCtD
Famotidine—Pruritus—Etoposide—hematologic cancer	3.67e-05	0.000131	CcSEcCtD
Famotidine—Shock—Prednisone—hematologic cancer	3.66e-05	0.00013	CcSEcCtD
Famotidine—Arrhythmia—Epirubicin—hematologic cancer	3.66e-05	0.00013	CcSEcCtD
Famotidine—Pain—Dexamethasone—hematologic cancer	3.65e-05	0.00013	CcSEcCtD
Famotidine—Pain—Betamethasone—hematologic cancer	3.65e-05	0.00013	CcSEcCtD
Famotidine—Alopecia—Epirubicin—hematologic cancer	3.62e-05	0.000129	CcSEcCtD
Famotidine—Nausea—Gemcitabine—hematologic cancer	3.61e-05	0.000128	CcSEcCtD
Famotidine—Vomiting—Cisplatin—hematologic cancer	3.6e-05	0.000128	CcSEcCtD
Famotidine—Mental disorder—Epirubicin—hematologic cancer	3.59e-05	0.000128	CcSEcCtD
Famotidine—Erythema multiforme—Doxorubicin—hematologic cancer	3.58e-05	0.000127	CcSEcCtD
Famotidine—Rash—Cisplatin—hematologic cancer	3.57e-05	0.000127	CcSEcCtD
Famotidine—Dermatitis—Cisplatin—hematologic cancer	3.57e-05	0.000127	CcSEcCtD
Famotidine—Diarrhoea—Etoposide—hematologic cancer	3.55e-05	0.000126	CcSEcCtD
Famotidine—Anorexia—Prednisone—hematologic cancer	3.54e-05	0.000126	CcSEcCtD
Famotidine—Tinnitus—Doxorubicin—hematologic cancer	3.53e-05	0.000126	CcSEcCtD
Famotidine—Anaemia—Methotrexate—hematologic cancer	3.52e-05	0.000125	CcSEcCtD
Famotidine—Feeling abnormal—Dexamethasone—hematologic cancer	3.52e-05	0.000125	CcSEcCtD
Famotidine—Feeling abnormal—Betamethasone—hematologic cancer	3.52e-05	0.000125	CcSEcCtD
Famotidine—Flushing—Doxorubicin—hematologic cancer	3.51e-05	0.000125	CcSEcCtD
Famotidine—Gastrointestinal pain—Betamethasone—hematologic cancer	3.49e-05	0.000124	CcSEcCtD
Famotidine—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.49e-05	0.000124	CcSEcCtD
Famotidine—Dysgeusia—Epirubicin—hematologic cancer	3.49e-05	0.000124	CcSEcCtD
Famotidine—Hypersensitivity—Triamcinolone—hematologic cancer	3.47e-05	0.000123	CcSEcCtD
Famotidine—Back pain—Epirubicin—hematologic cancer	3.45e-05	0.000123	CcSEcCtD
Famotidine—Dizziness—Etoposide—hematologic cancer	3.43e-05	0.000122	CcSEcCtD
Famotidine—Muscle spasms—Epirubicin—hematologic cancer	3.42e-05	0.000122	CcSEcCtD
Famotidine—Leukopenia—Methotrexate—hematologic cancer	3.41e-05	0.000121	CcSEcCtD
Famotidine—Urticaria—Betamethasone—hematologic cancer	3.39e-05	0.000121	CcSEcCtD
Famotidine—Urticaria—Dexamethasone—hematologic cancer	3.39e-05	0.000121	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.39e-05	0.000121	CcSEcCtD
Famotidine—Dizziness—Prednisolone—hematologic cancer	3.38e-05	0.00012	CcSEcCtD
Famotidine—Arrhythmia—Doxorubicin—hematologic cancer	3.38e-05	0.00012	CcSEcCtD
Famotidine—Asthenia—Triamcinolone—hematologic cancer	3.38e-05	0.00012	CcSEcCtD
Famotidine—Body temperature increased—Dexamethasone—hematologic cancer	3.37e-05	0.00012	CcSEcCtD
Famotidine—Body temperature increased—Betamethasone—hematologic cancer	3.37e-05	0.00012	CcSEcCtD
Famotidine—Abdominal pain—Betamethasone—hematologic cancer	3.37e-05	0.00012	CcSEcCtD
Famotidine—Abdominal pain—Dexamethasone—hematologic cancer	3.37e-05	0.00012	CcSEcCtD
Famotidine—Nausea—Cisplatin—hematologic cancer	3.36e-05	0.00012	CcSEcCtD
Famotidine—Insomnia—Prednisone—hematologic cancer	3.36e-05	0.00012	CcSEcCtD
Famotidine—Alopecia—Doxorubicin—hematologic cancer	3.35e-05	0.000119	CcSEcCtD
Famotidine—Paraesthesia—Prednisone—hematologic cancer	3.34e-05	0.000119	CcSEcCtD
Famotidine—Pruritus—Triamcinolone—hematologic cancer	3.33e-05	0.000118	CcSEcCtD
Famotidine—Cough—Methotrexate—hematologic cancer	3.32e-05	0.000118	CcSEcCtD
Famotidine—Mental disorder—Doxorubicin—hematologic cancer	3.32e-05	0.000118	CcSEcCtD
Famotidine—Convulsion—Methotrexate—hematologic cancer	3.3e-05	0.000117	CcSEcCtD
Famotidine—Vomiting—Etoposide—hematologic cancer	3.3e-05	0.000117	CcSEcCtD
Famotidine—Anaemia—Epirubicin—hematologic cancer	3.29e-05	0.000117	CcSEcCtD
Famotidine—Agitation—Epirubicin—hematologic cancer	3.27e-05	0.000116	CcSEcCtD
Famotidine—Dyspepsia—Prednisone—hematologic cancer	3.27e-05	0.000116	CcSEcCtD
Famotidine—Rash—Etoposide—hematologic cancer	3.27e-05	0.000116	CcSEcCtD
Famotidine—Dermatitis—Etoposide—hematologic cancer	3.27e-05	0.000116	CcSEcCtD
Famotidine—Headache—Etoposide—hematologic cancer	3.25e-05	0.000116	CcSEcCtD
Famotidine—Myalgia—Methotrexate—hematologic cancer	3.24e-05	0.000115	CcSEcCtD
Famotidine—Chest pain—Methotrexate—hematologic cancer	3.24e-05	0.000115	CcSEcCtD
Famotidine—Arthralgia—Methotrexate—hematologic cancer	3.24e-05	0.000115	CcSEcCtD
Famotidine—Decreased appetite—Prednisone—hematologic cancer	3.23e-05	0.000115	CcSEcCtD
Famotidine—Dysgeusia—Doxorubicin—hematologic cancer	3.23e-05	0.000115	CcSEcCtD
Famotidine—Rash—Prednisolone—hematologic cancer	3.23e-05	0.000115	CcSEcCtD
Famotidine—Dermatitis—Prednisolone—hematologic cancer	3.22e-05	0.000115	CcSEcCtD
Famotidine—Fatigue—Prednisone—hematologic cancer	3.2e-05	0.000114	CcSEcCtD
Famotidine—Headache—Prednisolone—hematologic cancer	3.2e-05	0.000114	CcSEcCtD
Famotidine—Syncope—Epirubicin—hematologic cancer	3.19e-05	0.000114	CcSEcCtD
Famotidine—Leukopenia—Epirubicin—hematologic cancer	3.19e-05	0.000113	CcSEcCtD
Famotidine—Back pain—Doxorubicin—hematologic cancer	3.19e-05	0.000113	CcSEcCtD
Famotidine—Constipation—Prednisone—hematologic cancer	3.18e-05	0.000113	CcSEcCtD
Famotidine—Muscle spasms—Doxorubicin—hematologic cancer	3.17e-05	0.000113	CcSEcCtD
Famotidine—Palpitations—Epirubicin—hematologic cancer	3.15e-05	0.000112	CcSEcCtD
Famotidine—Confusional state—Methotrexate—hematologic cancer	3.13e-05	0.000111	CcSEcCtD
Famotidine—Loss of consciousness—Epirubicin—hematologic cancer	3.13e-05	0.000111	CcSEcCtD
Famotidine—Dizziness—Triamcinolone—hematologic cancer	3.11e-05	0.000111	CcSEcCtD
Famotidine—Cough—Epirubicin—hematologic cancer	3.11e-05	0.000111	CcSEcCtD
Famotidine—Anaphylactic shock—Methotrexate—hematologic cancer	3.11e-05	0.000111	CcSEcCtD
Famotidine—Convulsion—Epirubicin—hematologic cancer	3.09e-05	0.00011	CcSEcCtD
Famotidine—Infection—Methotrexate—hematologic cancer	3.09e-05	0.00011	CcSEcCtD
Famotidine—Nausea—Etoposide—hematologic cancer	3.08e-05	0.00011	CcSEcCtD
Famotidine—Feeling abnormal—Prednisone—hematologic cancer	3.06e-05	0.000109	CcSEcCtD
Famotidine—Asthenia—Dexamethasone—hematologic cancer	3.06e-05	0.000109	CcSEcCtD
Famotidine—Asthenia—Betamethasone—hematologic cancer	3.06e-05	0.000109	CcSEcCtD
Famotidine—Anaemia—Doxorubicin—hematologic cancer	3.05e-05	0.000108	CcSEcCtD
Famotidine—Thrombocytopenia—Methotrexate—hematologic cancer	3.04e-05	0.000108	CcSEcCtD
Famotidine—Gastrointestinal pain—Prednisone—hematologic cancer	3.04e-05	0.000108	CcSEcCtD
Famotidine—Nausea—Prednisolone—hematologic cancer	3.04e-05	0.000108	CcSEcCtD
Famotidine—Chest pain—Epirubicin—hematologic cancer	3.03e-05	0.000108	CcSEcCtD
Famotidine—Myalgia—Epirubicin—hematologic cancer	3.03e-05	0.000108	CcSEcCtD
Famotidine—Arthralgia—Epirubicin—hematologic cancer	3.03e-05	0.000108	CcSEcCtD
Famotidine—Agitation—Doxorubicin—hematologic cancer	3.03e-05	0.000108	CcSEcCtD
Famotidine—Anxiety—Epirubicin—hematologic cancer	3.02e-05	0.000108	CcSEcCtD
Famotidine—Pruritus—Betamethasone—hematologic cancer	3.02e-05	0.000107	CcSEcCtD
Famotidine—Pruritus—Dexamethasone—hematologic cancer	3.02e-05	0.000107	CcSEcCtD
Famotidine—Vomiting—Triamcinolone—hematologic cancer	2.99e-05	0.000106	CcSEcCtD
Famotidine—Rash—Triamcinolone—hematologic cancer	2.97e-05	0.000106	CcSEcCtD
Famotidine—Dry mouth—Epirubicin—hematologic cancer	2.97e-05	0.000106	CcSEcCtD
Famotidine—Dermatitis—Triamcinolone—hematologic cancer	2.96e-05	0.000105	CcSEcCtD
Famotidine—Anorexia—Methotrexate—hematologic cancer	2.96e-05	0.000105	CcSEcCtD
Famotidine—Syncope—Doxorubicin—hematologic cancer	2.96e-05	0.000105	CcSEcCtD
Famotidine—Urticaria—Prednisone—hematologic cancer	2.95e-05	0.000105	CcSEcCtD
Famotidine—Leukopenia—Doxorubicin—hematologic cancer	2.95e-05	0.000105	CcSEcCtD
Famotidine—Headache—Triamcinolone—hematologic cancer	2.95e-05	0.000105	CcSEcCtD
Famotidine—Abdominal pain—Prednisone—hematologic cancer	2.94e-05	0.000105	CcSEcCtD
Famotidine—Body temperature increased—Prednisone—hematologic cancer	2.94e-05	0.000105	CcSEcCtD
Famotidine—Confusional state—Epirubicin—hematologic cancer	2.93e-05	0.000104	CcSEcCtD
Famotidine—Diarrhoea—Dexamethasone—hematologic cancer	2.92e-05	0.000104	CcSEcCtD
Famotidine—Diarrhoea—Betamethasone—hematologic cancer	2.92e-05	0.000104	CcSEcCtD
Famotidine—Palpitations—Doxorubicin—hematologic cancer	2.91e-05	0.000104	CcSEcCtD
Famotidine—Oedema—Epirubicin—hematologic cancer	2.91e-05	0.000103	CcSEcCtD
Famotidine—Anaphylactic shock—Epirubicin—hematologic cancer	2.91e-05	0.000103	CcSEcCtD
Famotidine—Loss of consciousness—Doxorubicin—hematologic cancer	2.9e-05	0.000103	CcSEcCtD
Famotidine—Infection—Epirubicin—hematologic cancer	2.89e-05	0.000103	CcSEcCtD
Famotidine—Cough—Doxorubicin—hematologic cancer	2.88e-05	0.000102	CcSEcCtD
Famotidine—Shock—Epirubicin—hematologic cancer	2.86e-05	0.000102	CcSEcCtD
Famotidine—Convulsion—Doxorubicin—hematologic cancer	2.86e-05	0.000102	CcSEcCtD
Famotidine—Thrombocytopenia—Epirubicin—hematologic cancer	2.85e-05	0.000101	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.83e-05	0.000101	CcSEcCtD
Famotidine—Dizziness—Betamethasone—hematologic cancer	2.82e-05	0.0001	CcSEcCtD
Famotidine—Dizziness—Dexamethasone—hematologic cancer	2.82e-05	0.0001	CcSEcCtD
Famotidine—Insomnia—Methotrexate—hematologic cancer	2.81e-05	0.0001	CcSEcCtD
Famotidine—Chest pain—Doxorubicin—hematologic cancer	2.81e-05	9.99e-05	CcSEcCtD
Famotidine—Myalgia—Doxorubicin—hematologic cancer	2.81e-05	9.99e-05	CcSEcCtD
Famotidine—Arthralgia—Doxorubicin—hematologic cancer	2.81e-05	9.99e-05	CcSEcCtD
Famotidine—Anxiety—Doxorubicin—hematologic cancer	2.8e-05	9.95e-05	CcSEcCtD
Famotidine—Nausea—Triamcinolone—hematologic cancer	2.79e-05	9.94e-05	CcSEcCtD
Famotidine—Paraesthesia—Methotrexate—hematologic cancer	2.79e-05	9.93e-05	CcSEcCtD
Famotidine—Anorexia—Epirubicin—hematologic cancer	2.77e-05	9.86e-05	CcSEcCtD
Famotidine—Somnolence—Methotrexate—hematologic cancer	2.76e-05	9.83e-05	CcSEcCtD
Famotidine—Dry mouth—Doxorubicin—hematologic cancer	2.74e-05	9.77e-05	CcSEcCtD
Famotidine—Hypersensitivity—Prednisone—hematologic cancer	2.74e-05	9.75e-05	CcSEcCtD
Famotidine—Dyspepsia—Methotrexate—hematologic cancer	2.73e-05	9.73e-05	CcSEcCtD
Famotidine—Vomiting—Betamethasone—hematologic cancer	2.71e-05	9.66e-05	CcSEcCtD
Famotidine—Vomiting—Dexamethasone—hematologic cancer	2.71e-05	9.66e-05	CcSEcCtD
Famotidine—Confusional state—Doxorubicin—hematologic cancer	2.71e-05	9.65e-05	CcSEcCtD
Famotidine—Decreased appetite—Methotrexate—hematologic cancer	2.7e-05	9.61e-05	CcSEcCtD
Famotidine—Rash—Betamethasone—hematologic cancer	2.69e-05	9.58e-05	CcSEcCtD
Famotidine—Rash—Dexamethasone—hematologic cancer	2.69e-05	9.58e-05	CcSEcCtD
Famotidine—Anaphylactic shock—Doxorubicin—hematologic cancer	2.69e-05	9.57e-05	CcSEcCtD
Famotidine—Oedema—Doxorubicin—hematologic cancer	2.69e-05	9.57e-05	CcSEcCtD
Famotidine—Dermatitis—Dexamethasone—hematologic cancer	2.69e-05	9.57e-05	CcSEcCtD
Famotidine—Dermatitis—Betamethasone—hematologic cancer	2.69e-05	9.57e-05	CcSEcCtD
Famotidine—Fatigue—Methotrexate—hematologic cancer	2.68e-05	9.53e-05	CcSEcCtD
Famotidine—Headache—Dexamethasone—hematologic cancer	2.67e-05	9.52e-05	CcSEcCtD
Famotidine—Headache—Betamethasone—hematologic cancer	2.67e-05	9.52e-05	CcSEcCtD
Famotidine—Infection—Doxorubicin—hematologic cancer	2.67e-05	9.51e-05	CcSEcCtD
Famotidine—Asthenia—Prednisone—hematologic cancer	2.67e-05	9.49e-05	CcSEcCtD
Famotidine—Pain—Methotrexate—hematologic cancer	2.66e-05	9.45e-05	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.65e-05	9.43e-05	CcSEcCtD
Famotidine—Shock—Doxorubicin—hematologic cancer	2.65e-05	9.42e-05	CcSEcCtD
Famotidine—Thrombocytopenia—Doxorubicin—hematologic cancer	2.63e-05	9.37e-05	CcSEcCtD
Famotidine—Pruritus—Prednisone—hematologic cancer	2.63e-05	9.36e-05	CcSEcCtD
Famotidine—Insomnia—Epirubicin—hematologic cancer	2.63e-05	9.36e-05	CcSEcCtD
Famotidine—Paraesthesia—Epirubicin—hematologic cancer	2.61e-05	9.29e-05	CcSEcCtD
Famotidine—Somnolence—Epirubicin—hematologic cancer	2.58e-05	9.2e-05	CcSEcCtD
Famotidine—Anorexia—Doxorubicin—hematologic cancer	2.56e-05	9.12e-05	CcSEcCtD
Famotidine—Feeling abnormal—Methotrexate—hematologic cancer	2.56e-05	9.11e-05	CcSEcCtD
Famotidine—Dyspepsia—Epirubicin—hematologic cancer	2.56e-05	9.11e-05	CcSEcCtD
Famotidine—Diarrhoea—Prednisone—hematologic cancer	2.54e-05	9.05e-05	CcSEcCtD
Famotidine—Gastrointestinal pain—Methotrexate—hematologic cancer	2.54e-05	9.04e-05	CcSEcCtD
Famotidine—Nausea—Dexamethasone—hematologic cancer	2.54e-05	9.02e-05	CcSEcCtD
Famotidine—Nausea—Betamethasone—hematologic cancer	2.54e-05	9.02e-05	CcSEcCtD
Famotidine—Decreased appetite—Epirubicin—hematologic cancer	2.53e-05	8.99e-05	CcSEcCtD
Famotidine—Fatigue—Epirubicin—hematologic cancer	2.51e-05	8.92e-05	CcSEcCtD
Famotidine—Constipation—Epirubicin—hematologic cancer	2.49e-05	8.85e-05	CcSEcCtD
Famotidine—Pain—Epirubicin—hematologic cancer	2.49e-05	8.85e-05	CcSEcCtD
Famotidine—Urticaria—Methotrexate—hematologic cancer	2.47e-05	8.78e-05	CcSEcCtD
Famotidine—Dizziness—Prednisone—hematologic cancer	2.46e-05	8.75e-05	CcSEcCtD
Famotidine—Body temperature increased—Methotrexate—hematologic cancer	2.46e-05	8.74e-05	CcSEcCtD
Famotidine—Abdominal pain—Methotrexate—hematologic cancer	2.46e-05	8.74e-05	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.45e-05	8.72e-05	CcSEcCtD
Famotidine—Insomnia—Doxorubicin—hematologic cancer	2.43e-05	8.66e-05	CcSEcCtD
Famotidine—Paraesthesia—Doxorubicin—hematologic cancer	2.42e-05	8.6e-05	CcSEcCtD
Famotidine—Feeling abnormal—Epirubicin—hematologic cancer	2.4e-05	8.53e-05	CcSEcCtD
Famotidine—Somnolence—Doxorubicin—hematologic cancer	2.39e-05	8.51e-05	CcSEcCtD
Famotidine—Gastrointestinal pain—Epirubicin—hematologic cancer	2.38e-05	8.46e-05	CcSEcCtD
Famotidine—Dyspepsia—Doxorubicin—hematologic cancer	2.37e-05	8.43e-05	CcSEcCtD
Famotidine—Vomiting—Prednisone—hematologic cancer	2.36e-05	8.41e-05	CcSEcCtD
Famotidine—Rash—Prednisone—hematologic cancer	2.34e-05	8.34e-05	CcSEcCtD
Famotidine—Dermatitis—Prednisone—hematologic cancer	2.34e-05	8.33e-05	CcSEcCtD
Famotidine—Decreased appetite—Doxorubicin—hematologic cancer	2.34e-05	8.32e-05	CcSEcCtD
Famotidine—Headache—Prednisone—hematologic cancer	2.33e-05	8.29e-05	CcSEcCtD
Famotidine—Fatigue—Doxorubicin—hematologic cancer	2.32e-05	8.25e-05	CcSEcCtD
Famotidine—Urticaria—Epirubicin—hematologic cancer	2.31e-05	8.22e-05	CcSEcCtD
Famotidine—Pain—Doxorubicin—hematologic cancer	2.3e-05	8.19e-05	CcSEcCtD
Famotidine—Constipation—Doxorubicin—hematologic cancer	2.3e-05	8.19e-05	CcSEcCtD
Famotidine—Body temperature increased—Epirubicin—hematologic cancer	2.3e-05	8.18e-05	CcSEcCtD
Famotidine—Abdominal pain—Epirubicin—hematologic cancer	2.3e-05	8.18e-05	CcSEcCtD
Famotidine—Hypersensitivity—Methotrexate—hematologic cancer	2.29e-05	8.14e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—RAC2—hematologic cancer	2.24e-05	0.000575	CbGpPWpGaD
Famotidine—Asthenia—Methotrexate—hematologic cancer	2.23e-05	7.93e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—DKK1—hematologic cancer	2.22e-05	0.000571	CbGpPWpGaD
Famotidine—Feeling abnormal—Doxorubicin—hematologic cancer	2.22e-05	7.89e-05	CcSEcCtD
Famotidine—Nausea—Prednisone—hematologic cancer	2.21e-05	7.86e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—STAT5B—hematologic cancer	2.2e-05	0.000566	CbGpPWpGaD
Famotidine—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.2e-05	7.83e-05	CcSEcCtD
Famotidine—Pruritus—Methotrexate—hematologic cancer	2.2e-05	7.82e-05	CcSEcCtD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	2.19e-05	0.000563	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—FHL2—hematologic cancer	2.18e-05	0.000561	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	2.17e-05	0.000557	CbGpPWpGaD
Famotidine—Hypersensitivity—Epirubicin—hematologic cancer	2.14e-05	7.62e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—ADCY7—hematologic cancer	2.14e-05	0.00055	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AGRN—hematologic cancer	2.14e-05	0.00055	CbGpPWpGaD
Famotidine—Urticaria—Doxorubicin—hematologic cancer	2.14e-05	7.6e-05	CcSEcCtD
Famotidine—Abdominal pain—Doxorubicin—hematologic cancer	2.13e-05	7.57e-05	CcSEcCtD
Famotidine—Body temperature increased—Doxorubicin—hematologic cancer	2.13e-05	7.57e-05	CcSEcCtD
Famotidine—CYP2C19—Metabolism—SMPD3—hematologic cancer	2.13e-05	0.000546	CbGpPWpGaD
Famotidine—Diarrhoea—Methotrexate—hematologic cancer	2.13e-05	7.56e-05	CcSEcCtD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	2.12e-05	0.000545	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CSF2—hematologic cancer	2.11e-05	0.000542	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—IL2RA—hematologic cancer	2.09e-05	0.000538	CbGpPWpGaD
Famotidine—Asthenia—Epirubicin—hematologic cancer	2.09e-05	7.42e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—XIAP—hematologic cancer	2.08e-05	0.000535	CbGpPWpGaD
Famotidine—Pruritus—Epirubicin—hematologic cancer	2.06e-05	7.32e-05	CcSEcCtD
Famotidine—Dizziness—Methotrexate—hematologic cancer	2.05e-05	7.31e-05	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—JAK1—hematologic cancer	2.04e-05	0.000524	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PRKCG—hematologic cancer	2.04e-05	0.000524	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SH2B3—hematologic cancer	2.03e-05	0.000521	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SMARCA4—hematologic cancer	2.03e-05	0.000521	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—IDH2—hematologic cancer	2.03e-05	0.000521	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HMMR—hematologic cancer	2.03e-05	0.000521	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GZMB—hematologic cancer	2.02e-05	0.000518	CbGpPWpGaD
Famotidine—Diarrhoea—Epirubicin—hematologic cancer	1.99e-05	7.08e-05	CcSEcCtD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	1.98e-05	0.000509	CbGpPWpGaD
Famotidine—Hypersensitivity—Doxorubicin—hematologic cancer	1.98e-05	7.05e-05	CcSEcCtD
Famotidine—SLC22A2—Neuronal System—MDM2—hematologic cancer	1.98e-05	0.000508	CbGpPWpGaD
Famotidine—Vomiting—Methotrexate—hematologic cancer	1.98e-05	7.03e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—CTNNA1—hematologic cancer	1.97e-05	0.000506	CbGpPWpGaD
Famotidine—Rash—Methotrexate—hematologic cancer	1.96e-05	6.97e-05	CcSEcCtD
Famotidine—Dermatitis—Methotrexate—hematologic cancer	1.96e-05	6.96e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—EIF4EBP1—hematologic cancer	1.96e-05	0.000503	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HSPB1—hematologic cancer	1.96e-05	0.000503	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCL3—hematologic cancer	1.96e-05	0.000503	CbGpPWpGaD
Famotidine—Headache—Methotrexate—hematologic cancer	1.95e-05	6.93e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—PTHLH—hematologic cancer	1.93e-05	0.000497	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SDC1—hematologic cancer	1.93e-05	0.000497	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	1.93e-05	0.000496	CbGpPWpGaD
Famotidine—Asthenia—Doxorubicin—hematologic cancer	1.93e-05	6.87e-05	CcSEcCtD
Famotidine—Dizziness—Epirubicin—hematologic cancer	1.92e-05	6.84e-05	CcSEcCtD
Famotidine—SLC22A2—Metabolism—ARNTL—hematologic cancer	1.91e-05	0.00049	CbGpPWpGaD
Famotidine—Pruritus—Doxorubicin—hematologic cancer	1.9e-05	6.77e-05	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—IL2RA—hematologic cancer	1.9e-05	0.000489	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTGER4—hematologic cancer	1.88e-05	0.000484	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—LCK—hematologic cancer	1.87e-05	0.000482	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	1.87e-05	0.000481	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—B3GAT1—hematologic cancer	1.86e-05	0.000478	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—DCK—hematologic cancer	1.86e-05	0.000478	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ASNS—hematologic cancer	1.86e-05	0.000478	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CA9—hematologic cancer	1.85e-05	0.000477	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ACP5—hematologic cancer	1.85e-05	0.000477	CbGpPWpGaD
Famotidine—Vomiting—Epirubicin—hematologic cancer	1.85e-05	6.58e-05	CcSEcCtD
Famotidine—Nausea—Methotrexate—hematologic cancer	1.85e-05	6.57e-05	CcSEcCtD
Famotidine—Diarrhoea—Doxorubicin—hematologic cancer	1.84e-05	6.55e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—H3F3A—hematologic cancer	1.84e-05	0.000472	CbGpPWpGaD
Famotidine—Rash—Epirubicin—hematologic cancer	1.83e-05	6.52e-05	CcSEcCtD
Famotidine—Dermatitis—Epirubicin—hematologic cancer	1.83e-05	6.52e-05	CcSEcCtD
Famotidine—SLC22A2—Metabolism—NCOR2—hematologic cancer	1.83e-05	0.00047	CbGpPWpGaD
Famotidine—Headache—Epirubicin—hematologic cancer	1.82e-05	6.48e-05	CcSEcCtD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	1.82e-05	0.000467	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.8e-05	0.000462	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PRKCZ—hematologic cancer	1.79e-05	0.000459	CbGpPWpGaD
Famotidine—Dizziness—Doxorubicin—hematologic cancer	1.78e-05	6.33e-05	CcSEcCtD
Famotidine—CYP2C19—Metabolism—HDC—hematologic cancer	1.76e-05	0.000453	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CG—hematologic cancer	1.75e-05	0.000449	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—IDH1—hematologic cancer	1.74e-05	0.000448	CbGpPWpGaD
Famotidine—Nausea—Epirubicin—hematologic cancer	1.73e-05	6.15e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—PARP1—hematologic cancer	1.72e-05	0.000443	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ABCC3—hematologic cancer	1.72e-05	0.000443	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TXN—hematologic cancer	1.72e-05	0.000443	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTO1—hematologic cancer	1.72e-05	0.000443	CbGpPWpGaD
Famotidine—Vomiting—Doxorubicin—hematologic cancer	1.71e-05	6.09e-05	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—FBXW7—hematologic cancer	1.7e-05	0.000436	CbGpPWpGaD
Famotidine—Rash—Doxorubicin—hematologic cancer	1.7e-05	6.04e-05	CcSEcCtD
Famotidine—Dermatitis—Doxorubicin—hematologic cancer	1.69e-05	6.03e-05	CcSEcCtD
Famotidine—SLC22A2—Metabolism—SPHK1—hematologic cancer	1.69e-05	0.000434	CbGpPWpGaD
Famotidine—Headache—Doxorubicin—hematologic cancer	1.69e-05	6e-05	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—ALB—hematologic cancer	1.68e-05	0.000433	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HDAC2—hematologic cancer	1.66e-05	0.000428	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCR4—hematologic cancer	1.66e-05	0.000428	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	1.64e-05	0.000422	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CBL—hematologic cancer	1.62e-05	0.000417	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—UGT1A1—hematologic cancer	1.62e-05	0.000417	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CDA—hematologic cancer	1.61e-05	0.000414	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL3—hematologic cancer	1.6e-05	0.000412	CbGpPWpGaD
Famotidine—Nausea—Doxorubicin—hematologic cancer	1.6e-05	5.69e-05	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—PIK3CG—hematologic cancer	1.58e-05	0.000407	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTPN1—hematologic cancer	1.58e-05	0.000405	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC22A1—hematologic cancer	1.58e-05	0.000405	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CRABP1—hematologic cancer	1.58e-05	0.000405	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PTPN11—hematologic cancer	1.56e-05	0.0004	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—RASGRP1—hematologic cancer	1.55e-05	0.000399	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PC—hematologic cancer	1.55e-05	0.000399	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HSP90AA1—hematologic cancer	1.55e-05	0.000397	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SYK—hematologic cancer	1.55e-05	0.000397	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ALOX5—hematologic cancer	1.54e-05	0.000395	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CD—hematologic cancer	1.53e-05	0.000394	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CREB1—hematologic cancer	1.51e-05	0.000388	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC35B2—hematologic cancer	1.5e-05	0.000385	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GBA—hematologic cancer	1.5e-05	0.000385	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—STAT1—hematologic cancer	1.49e-05	0.000383	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NUP98—hematologic cancer	1.49e-05	0.000383	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCL2—hematologic cancer	1.48e-05	0.000379	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL6R—hematologic cancer	1.47e-05	0.000378	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3R1—hematologic cancer	1.45e-05	0.000372	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ADCY7—hematologic cancer	1.45e-05	0.000371	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NCOA3—hematologic cancer	1.45e-05	0.000371	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NUP214—hematologic cancer	1.43e-05	0.000369	CbGpPWpGaD
Famotidine—SLC22A2—Transmission across Chemical Synapses—HRAS—hematologic cancer	1.42e-05	0.000364	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—JAK2—hematologic cancer	1.41e-05	0.000362	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ABCG2—hematologic cancer	1.41e-05	0.000361	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—MTR—hematologic cancer	1.41e-05	0.000361	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—MAP2K1—hematologic cancer	1.4e-05	0.00036	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GRB2—hematologic cancer	1.4e-05	0.000359	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CD—hematologic cancer	1.39e-05	0.000358	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PDGFA—hematologic cancer	1.39e-05	0.000358	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ENO2—hematologic cancer	1.38e-05	0.000354	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KITLG—hematologic cancer	1.37e-05	0.000353	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—MTAP—hematologic cancer	1.37e-05	0.000352	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—STAT5A—hematologic cancer	1.34e-05	0.000345	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CB—hematologic cancer	1.34e-05	0.000344	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTT1—hematologic cancer	1.34e-05	0.000344	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CDKN2B—hematologic cancer	1.33e-05	0.000342	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3R1—hematologic cancer	1.32e-05	0.000338	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SDC1—hematologic cancer	1.31e-05	0.000336	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CD86—hematologic cancer	1.29e-05	0.00033	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—JAK2—hematologic cancer	1.28e-05	0.000329	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HES1—hematologic cancer	1.27e-05	0.000326	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NCOR1—hematologic cancer	1.26e-05	0.000324	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.25e-05	0.000322	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGF1—hematologic cancer	1.25e-05	0.00032	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CSF2—hematologic cancer	1.25e-05	0.00032	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FOXO1—hematologic cancer	1.23e-05	0.000316	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—IL2—hematologic cancer	1.23e-05	0.000316	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PDGFRB—hematologic cancer	1.23e-05	0.000315	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—FHL2—hematologic cancer	1.22e-05	0.000314	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CB—hematologic cancer	1.21e-05	0.000312	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PDGFRA—hematologic cancer	1.21e-05	0.00031	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—JAK1—hematologic cancer	1.2e-05	0.000309	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PRKCG—hematologic cancer	1.2e-05	0.000309	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AGRN—hematologic cancer	1.2e-05	0.000308	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ALB—hematologic cancer	1.17e-05	0.000301	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—IDH2—hematologic cancer	1.14e-05	0.000292	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HMMR—hematologic cancer	1.14e-05	0.000292	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL2RA—hematologic cancer	1.12e-05	0.000289	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL2—hematologic cancer	1.12e-05	0.000287	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TERT—hematologic cancer	1.11e-05	0.000286	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CD44—hematologic cancer	1.11e-05	0.000286	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NQO1—hematologic cancer	1.11e-05	0.000286	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—HRAS—hematologic cancer	1.09e-05	0.000279	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PDGFB—hematologic cancer	1.08e-05	0.000279	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.07e-05	0.000275	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ARNTL—hematologic cancer	1.07e-05	0.000274	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TSC2—hematologic cancer	1.06e-05	0.000272	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYCS—hematologic cancer	1.05e-05	0.00027	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HSP90AA1—hematologic cancer	1.04e-05	0.000268	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ACP5—hematologic cancer	1.04e-05	0.000267	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CA9—hematologic cancer	1.04e-05	0.000267	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NCOR2—hematologic cancer	1.02e-05	0.000263	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGFR3—hematologic cancer	1.02e-05	0.000262	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MAPK14—hematologic cancer	1.01e-05	0.000259	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ESR1—hematologic cancer	9.9e-06	0.000255	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FN1—hematologic cancer	9.78e-06	0.000251	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—IDH1—hematologic cancer	9.76e-06	0.000251	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—BAD—hematologic cancer	9.67e-06	0.000248	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NFKBIA—hematologic cancer	9.67e-06	0.000248	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TXN—hematologic cancer	9.65e-06	0.000248	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ABCC3—hematologic cancer	9.65e-06	0.000248	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTO1—hematologic cancer	9.65e-06	0.000248	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOTCH1—hematologic cancer	9.57e-06	0.000246	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SPHK1—hematologic cancer	9.44e-06	0.000243	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CD80—hematologic cancer	9.38e-06	0.000241	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CG—hematologic cancer	9.36e-06	0.000241	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KIT—hematologic cancer	9.36e-06	0.000241	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—NRAS—hematologic cancer	9.36e-06	0.000241	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTP1—hematologic cancer	9.27e-06	0.000238	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTPN11—hematologic cancer	9.2e-06	0.000236	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—UGT1A1—hematologic cancer	9.07e-06	0.000233	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—MAPK3—hematologic cancer	8.97e-06	0.00023	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CREB1—hematologic cancer	8.91e-06	0.000229	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CRABP1—hematologic cancer	8.83e-06	0.000227	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC22A1—hematologic cancer	8.83e-06	0.000227	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—BRAF—hematologic cancer	8.8e-06	0.000226	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ABCB1—hematologic cancer	8.77e-06	0.000225	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCL2—hematologic cancer	8.72e-06	0.000224	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL6R—hematologic cancer	8.69e-06	0.000223	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CREBBP—hematologic cancer	8.68e-06	0.000223	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ALOX5—hematologic cancer	8.6e-06	0.000221	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NCOR1—hematologic cancer	8.52e-06	0.000219	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTM1—hematologic cancer	8.52e-06	0.000219	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NUP98—hematologic cancer	8.33e-06	0.000214	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MAP2K1—hematologic cancer	8.28e-06	0.000213	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CD—hematologic cancer	8.23e-06	0.000212	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CA—hematologic cancer	8.15e-06	0.00021	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ADCY7—hematologic cancer	8.09e-06	0.000208	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NCOA3—hematologic cancer	8.09e-06	0.000208	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—KRAS—hematologic cancer	8.06e-06	0.000207	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NUP214—hematologic cancer	8.03e-06	0.000206	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	7.95e-06	0.000204	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGF2—hematologic cancer	7.88e-06	0.000203	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—MTR—hematologic cancer	7.87e-06	0.000202	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ABCG2—hematologic cancer	7.87e-06	0.000202	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3R1—hematologic cancer	7.77e-06	0.0002	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ENO2—hematologic cancer	7.72e-06	0.000198	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—JAK2—hematologic cancer	7.55e-06	0.000194	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—MTHFR—hematologic cancer	7.53e-06	0.000193	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTT1—hematologic cancer	7.48e-06	0.000192	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CA—hematologic cancer	7.4e-06	0.00019	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MDM2—hematologic cancer	7.37e-06	0.000189	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.37e-06	0.000189	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SDC1—hematologic cancer	7.31e-06	0.000188	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CB—hematologic cancer	7.17e-06	0.000184	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MTOR—hematologic cancer	7.17e-06	0.000184	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.99e-06	0.00018	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	6.9e-06	0.000177	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—HRAS—hematologic cancer	6.85e-06	0.000176	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CDKN1B—hematologic cancer	6.73e-06	0.000173	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—AKT1—hematologic cancer	6.66e-06	0.000171	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CASP3—hematologic cancer	6.6e-06	0.00017	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.6e-06	0.00017	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL2—hematologic cancer	6.59e-06	0.000169	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL6—hematologic cancer	6.56e-06	0.000168	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCND1—hematologic cancer	6.42e-06	0.000165	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—JUN—hematologic cancer	6.41e-06	0.000165	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CG—hematologic cancer	6.32e-06	0.000163	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NQO1—hematologic cancer	6.22e-06	0.00016	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CD44—hematologic cancer	6.22e-06	0.00016	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CDKN1A—hematologic cancer	6.21e-06	0.00016	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTEN—hematologic cancer	6.2e-06	0.000159	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.09e-06	0.000157	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MAPK8—hematologic cancer	6.06e-06	0.000156	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—AKT1—hematologic cancer	6.05e-06	0.000155	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EP300—hematologic cancer	5.91e-06	0.000152	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYCS—hematologic cancer	5.88e-06	0.000151	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CREBBP—hematologic cancer	5.86e-06	0.000151	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	5.85e-06	0.00015	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SRC—hematologic cancer	5.75e-06	0.000148	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—VEGFA—hematologic cancer	5.6e-06	0.000144	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CD—hematologic cancer	5.56e-06	0.000143	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—STAT3—hematologic cancer	5.54e-06	0.000142	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NRAS—hematologic cancer	5.53e-06	0.000142	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ALB—hematologic cancer	5.49e-06	0.000141	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MAPK3—hematologic cancer	5.3e-06	0.000136	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.26e-06	0.000135	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3R1—hematologic cancer	5.25e-06	0.000135	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTP1—hematologic cancer	5.19e-06	0.000133	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MYC—hematologic cancer	5.15e-06	0.000132	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TGFB1—hematologic cancer	5.14e-06	0.000132	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.02e-06	0.000129	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ABCB1—hematologic cancer	4.91e-06	0.000126	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CB—hematologic cancer	4.85e-06	0.000125	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTM1—hematologic cancer	4.77e-06	0.000123	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NCOR1—hematologic cancer	4.77e-06	0.000123	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KRAS—hematologic cancer	4.76e-06	0.000122	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CA—hematologic cancer	4.37e-06	0.000112	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TP53—hematologic cancer	4.23e-06	0.000109	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—MTHFR—hematologic cancer	4.21e-06	0.000108	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PTEN—hematologic cancer	4.19e-06	0.000108	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HRAS—hematologic cancer	4.05e-06	0.000104	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—EP300—hematologic cancer	3.99e-06	0.000103	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL6—hematologic cancer	3.87e-06	9.95e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.71e-06	9.54e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AKT1—hematologic cancer	3.57e-06	9.18e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.54e-06	9.1e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.28e-06	8.43e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.11e-06	8e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ALB—hematologic cancer	3.07e-06	7.89e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CA—hematologic cancer	2.95e-06	7.59e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	2.94e-06	7.55e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.71e-06	6.97e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AKT1—hematologic cancer	2.41e-06	6.2e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PTEN—hematologic cancer	2.34e-06	6.02e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—EP300—hematologic cancer	2.24e-06	5.74e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.65e-06	4.25e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AKT1—hematologic cancer	1.35e-06	3.47e-05	CbGpPWpGaD
